July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Pars plana vitrectomy for the treatment of uveitis
Author Affiliations & Notes
  • Christopher Ryan Henry
    Retina Consultants of Houston, Houston, Texas, United States
    Blanton Eye Institute , Houston, Texas, United States
  • Matthias Becker
    Department of Ophthalmology, Triemli Hospital, Zurich, Switzerland
  • Yang Yongsheng
    Eye Hospital of China Academy of Chinese Medical Sciences, Beijing, China
    Bascom Palmer Eye Institute, Miami, Florida, United States
  • Janet L. Davis
    Bascom Palmer Eye Institute, Miami, Florida, United States
  • Footnotes
    Commercial Relationships   Christopher Henry, None; Matthias Becker, None; Yang Yongsheng, None; Janet Davis, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4199. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Christopher Ryan Henry, Matthias Becker, Yang Yongsheng, Janet L. Davis; Pars plana vitrectomy for the treatment of uveitis. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4199.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the clinical utility of pars plana vitrectomy (PPV) in the treatment of uveitis.

Methods : A systematic review was conducted for relevant articles on pars plana vitrectomy for the management of uveitis. Results from the studies were compiled and analyzed.

Results : Thirty-four articles, published from 2005 through 2015, were included in the final analysis. Thirty-two manuscripts were from retrospective case series and 2 manuscripts were from randomized pilot studies. Overall, 627 patients and 708 total eyes undergoing PPV for uveitis were included. The average reported age off all patients was 43.4 years. The median duration of uveitis prior to PPV reported in the studies was 36.1 months (range 4-198). The median follow-up after PPV reported in the studies was 18.9 months (range 2-114). Vision was reported for 519 eyes and was improved in 356 eyes (69%), unchanged in 95 eyes (18%), and worse in 68 eyes (13%) following PPV. Pre-operatively, 157/300 (52%) eyes in these studies had documented cystoid macular edema compared to 112/300 (37%) eyes postoperatively. Median use of oral corticosteroids improved from 48% pre-operatively, to 12% post-operatively amongst the reporting studies. Median use of other immunosuppressive medications decreased from 56% pre-operatively, to 36% post-operatively amongst the reporting studies. The median Scottish Intercollegiate Guidelines Network (SIGN) level of evidence grade was 3 and the median Oxford Center for Evidence-based Medicine (OCEBM) level of evidence grade was 4. Fewer than 50% of the articles in the current study applied Standardization of Uveitis Nomenclature (SUN) criteria in regards to reporting the anatomic location of uveitis, fewer than 25% of studies applied SUN criteria in regards to the reporting of anterior chamber cells before and after PPV, fewer than 10% of studies applied SUN criteria to the grading of anterior chamber flare before and after PPV, and fewer than 10% of studies applied standardized criteria to the grading of vitreous haze after PPV.

Conclusions : The current systematic review demonstrates favorable outcomes of PPV in the management of uveitis, however the quality of data remains limited by a lack of application of standardized reporting outcomes, limitations in study design, and a paucity of prospective data.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×